Peer support for adolescents and emerging adults with sickle cell pain: promoting engagement in cognitive behavioral therapy
Active Cooperative Agreement Awarded Last action
- Award ID
- UH3HL165839
- Recipient
-
University Of Pittsburgh - Of The Commonwealth System Of Higher Education UEI MKAGLD59JRL1
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $5,588,899
Award facts
- Assistance listing
- 93.279 Drug Use and Addiction Research Programs
- Completion date 65% complete
- Funding agency
- National Institute of Neurological Disorders and Stroke National Institutes of Health, Department of Health and Human Services
- Place of performance
- Pittsburgh, PA 15222, USA
Award details come from USAspending.gov.
Description
- Abstract
- Pain is the clinical hallmark of sickle cell disease (SCD), yet pain management remains inadequate for many in this population due to lack of evidence-based pain treatment approaches for SCD, and due to stigma and implicit bias in the healthcare system. Black adolescents and young adults (ayas, ages 16-30) with SCD are particularly vulnerable as they endure repeat hospitalizations due to pain crises while coping with stigma and related stressors, as well as the other challenges of transitioning to adulthood. Opioids are the primary agent used in chronic SCD pain management, despite evidence that they provide poor long-term relief and lead to negative physical and psychological consequences. Psychosocial interventions that teach cognitive and behavioral strategies can simultaneously reduce pain and stigma and enhance mood in patients with SCD. Cognitive behavioral therapy (CBT) is the primary behavioral health approach to managing pain in the general population, and digital CBT has expanded its accessibility. In SCD and other minority populations, we have demonstrated that a low-cost, scalable, technology-delivered version of CBT is feasible and can be effective for addressing stress and pain. We have learned that personalized support can improve engagement with digital CBT. We will now test a personalized approach customized for ayas with SCD using peer support delivered through community-based organizations (cbos). We will conduct a multisite, randomized controlled trial of digital CBT to understand the level of support needed to achieve benefits for reducing pain and stigma. Our peer support for adolescents and emerging adults with sickle cell pain: promoting engagement in cognitive behavioral therapy (presence) study aims to reduce pain, opioid use, and healthcare utilization among ayas with SCD. During the UG3 phase, we will leverage an established infrastructure for delivering virtual peer support interventions, existing digital CBT programs tailored by and for people with SCD, and partnerships with cbos to jointly refine the study design, digital CBT content, and peer support component and work with the heal ERN CCC and DCC to prepare for the UH3 trial. After meeting UG3 milestones and transitioning to the UH3 phase, we will randomize 470 ayas with frequent pain (³4 days/WK) over the past ³3 months to one of 3 treatment groups: 1) a digital CBT program with weekly one-on-one peer support provided via text and/or telephone based on participant preference (CBT+peer), 2) the same digital CBT program without peer support (self-guided CBT), or 3) usual care (UC). We first hypothesize that ayas receiving either digital CBT treatment (CBT+ peer or self-guided CBT) will have better pain and mental health outcomes than ayas receiving UC at 6 months. Second, we hypothesize that CBT+peer will be associated with improved program engagement and pain and mental health outcomes at 6 months compared with self-guided CBT. The presence trial will determine effectiveness of digital CBT for pain management among ayas with SCD, a critical step toward future wide-scale deployment as part of routine SCD care.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $351,124 | |
| Amendment | $351,124 | |
| Amendment | $1,502,212 | |
| Amendment | $1,502,212 | |
| Amendment | $351,124 | |
| Amendment | $0 | |
| Original award | $1,531,103 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Connecticut Children's Medical Center | $45,770 | |
| Virginia Commonwealth University | $36,586 | |
| Emory University | $78,100 | |
| Seattle Children's Hospital | $22,246 | |
| Wake Forest University Health Sciences | $10,150 | |
| Emory University | $0 | |
| Connecticut Children's Medical Center | $109,000 |
Quick answers
Who received award UH3HL165839?
UH3HL165839 was awarded to University Of Pittsburgh - Of The Commonwealth System Of Higher Education by National Heart Lung and Blood Institute (National Institutes of Health) on August 10, 2023.
How much is award UH3HL165839 worth?
$5,588,899 has been obligated on UH3HL165839.
Which agency awarded UH3HL165839?
National Heart Lung and Blood Institute (National Institutes of Health) awarded UH3HL165839, with funding from National Institute of Neurological Disorders and Stroke (National Institutes of Health).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award